Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-09-08
1990-05-29
Shen, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514326, 514340, 514378, 514859, 514863, 546209, 546275, 548240, 548243, A61K 3144, A61K 31445, A61K 3142, C07D26104
Patent
active
049296302
ABSTRACT:
The present invention is directed to certain 3,5 substituted, 4,5-dihydroisoxazoles, and methods for their use. These compounds are transglutaminase inhibitors, and are particularly effective in the inhibition of epidermal transglutaminase and the treatment of acne.
REFERENCES:
patent: 4276299 (1981-06-01), Della Bella et al.
patent: 4277485 (1981-07-01), Durant et al.
patent: 4283403 (1981-08-01), Davenport
patent: 4298744 (1981-11-01), Kelly et al.
patent: 4451476 (1984-05-01), Diana
patent: 4497812 (1985-02-01), Creuzet et al.
patent: 4499090 (1985-02-01), Creuzet et al.
P. A. Wade et al., Tetrahedron Letters, vol. 23, (No. 44), 4563-4566 (1982), Cyanogen Chloride n-Oxide Cycloaddititions, A Simple Short Route to AT-125.
Chemical Abstracts, vol. 78, (No. 13), Apr. 2, 1973, p. 466, Abstract No. 84476f.
Schasteen et al., "The Binding Mechanism of Glutathione and the Anti-Tumor Drug . . . ", Biochemical and Biophysical Res. Comm., 112(2), 564-70 (1983).
Tso et al., "Mechanism of Inactivation of Glutamine Amidotransferases by the Antitumor Drug . . . ," J. Biol. Chem., 255(14), 6734-38 (1980).
McGuire et al., "Phase II Trial of Acivivin in Patients with Advanced Epithelial Ovarian Carcinoma", Investigational New Drugs, 4, 49-52 (1986).
Lui et al., "Biochemical Pharmacology of Acivicin in Rat Hempatoma Cells", Biochem. Pharmacology, 31(21), 3469-73 (1982).
Poster et al., "Acivicin", Cancer Clin. Trials, 4, 327-30 (1981).
Maroun et al., "Phase II Study of Acivicin in Colorectal Carcinoma", Cancer Treatment Reports, 68(9), 1121-23 (1984).
Jayaram et al., "Mechanism of Resistance of a Variant of P388 Leukemia to . . . ," Cancer Research, 45, 207-12 (1985).
Denton et al., "Rapid in Vivo Inactivation by Acivicin of CTP Synthesase . . . ," Life Sciences, 30(13), 1073-80 (1982).
McGovern et al., "Pharmacokinetic and Biochemical Studies on Acivicin in Phase I Clinical Trials", cancer Research 45, 4460-63 (1985).
"Information Update", Drugs of the Future, 8(4), 351-54 (1983).
"Information Update", Drugs of the Future, 4(4), 252-54 (1979).
Martin et al., "Derivatization and Purification of Acivicin", The J. of Antibiotics, 34(4), 459-61 (1981).
Capraro et al., "The Use of Acivicin in Determination of Rate Constants for Turnover of Rat Renal . . . ," J. Biological Chem., 260(6), 3408-12 (1985).
Jayaram et al., "Mechanism of Resistance of a Variant of P388 Leukemia to . . . ," Cancer Research, 45, 207-12 (1985).
Weber et al., "Control of Enzymic Programs and Nucleotide Pattern in Cancer Cells by Activicin and Tiazofurin", Adv. in Enzyme Regulation, 22, 69-93 (1984).
Earhart et al., "Acivicin in 1985", Adv. in Enzyme Regulations, 24, 179-243 (1986).
Carl et al., "Protease-Activated Prodrugs for Cancer Chemotherapy", Proc. Natl. Acad. Sci. U.S.A., 77(4), 2224-28 (1980).
Chakravarty et al., "Plasmin-Activated Prodrugs for Cancer Therapy", J. Med. Chem., 26, 638-44 (1983).
Wade et al., "Benzenesulfonyl Carbonitrile Oxide", Tetrahedron, 40(3), 601-11 (1984).
De Young et al., "Tranglutaminase Activity in Human and Rabbit Ear Comedogenesis", J. of Invest. Dermatology, 82(3), 275-79 (1984).
Abstract of U.S. Pat. No. 3,090,788 (Derwent Abs. No. 7639f).
Abstract of Japanese Kokoku No. 9143/67 (Derwent Abs. No. 26790F).
Abstract of Japanese Kokoku No. 9145/67 (Derwent Abs. No. 26792F).
Abstract of Japanese Kokoku No. 9830/67 (Derwent Abs. No. 26974F).
Abstract of Japanese Kokai No. 123061/74 (Derwent Abs. No. 16812W).
Abstract of DT Patent No. 2514984 (Derwent Abs. No. 74374W).
Abstract of Japanese Kokai No. 112371/79 (Derwent Abs. No. 19044B).
Abstract of Japanese Kokai No. 44665/79 (Derwent Abs. No. 37963B).
Abstract of Japanese Kokai No. 73773/79 (Derwent Abs. No. 55096B).
Abstract of BE Patent No. 867261 (Derwent Abs. No. 84158B).
Abstract of U.S. Pat. No. 4,188,324 (Derwent Abs. No. 14626C).
Abstract of U.S. Pat. No. 4,232,164 (Derwent Abs. No. 84300C).
Abstract of U.S. Pat. No. 4,256,898 (Derwent Abs. No. 25346C).
Abstract of U.S. Pat. No. 4,275,213 (Derwent Abs. No. 51607D).
Abstract of U.S. Pat. No. 4,275,214 (Derwent Abs. No. 51608D).
Abstract of BE Patent No. 887954 (Derwent Abs. No. 71771D).
Abstract of U.S. Pat. No. 4,298,744 (Derwent Abs. No. 87203D).
Abstract of EP Patent No. 81783 (Derwent Abs. No. 61633K).
Abstract of EP Patent No. 114993 (Derwent Abs. No. 84 196505).
Abstract of U.S. Pat. No. 4,479,941 (Derwent Abs. No. 84-287964).
Carl et al., Chem. Abst. 95-116014y (1981).
Cariello et al., Chem. Abst. 103-40927 (1985).
Castelhano et al., Chem. Abst. 110-7607h (1989).
Castelhano et al., Chem. Abst. 110-193339p (1989).
Castelhano Arlindo L.
DeYoung Lawrence M.
Krantz Alexander
Pliura Diana H.
Venuti Michael C.
Johnson Lester E.
Krubiner Alan M.
Moran Tom M.
Shen Cecilia
Syntex (U.S.A.) Inc.
LandOfFree
Transglutaminase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transglutaminase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transglutaminase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-521191